Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer

N. A. Spry, L. Kristjanson, B. Hooton, L. Hayden, G. Neerhut, H. Gurney, T. Corica, E. Korbel, S. Weinstein, K. McCaul

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Health-related quality of life (HQOL) research is a means of broadening the assessment of treatment effects. This longitudinal study investigated the dynamic change to quality of life (QOL) and testosterone dependant physiology in men commencing an intermittent maximal androgen blockade program (IMAB). Two hundred and fifty men were accrued to the multi-centre study of IMAB (Flutamide 250 mg TDS, Leuprolide 22.5 mg depot) ceasing treatment after 9 months if PSA <4 ng/ml, and restarting when PSA >20 ng/ml. QOL was assessed every 3 months for 30 months using the EORTC QLQ-C30 and EORTC QLQ-PR25 module. Data completion for the whole study was 90%. At baseline, our cohort was less symptomatic and had better function than the EORTC reference cohort, which may be related to a shift in clinical practice with time. Testosterone suppression (AS) lead to a significant reduction in global HQOL and deterioration in most function and symptom scales. During the off period, there was a trend of progressive improvement in HQOL that paralleled testosterone recovery but was slower than the rate of deterioration during the treatment phase. Maximum recovery of HQOL occurred most frequently by months 9-12. Testosterone recovery was slower and less complete in older men, and lead to concomitant poorer HOQL recovery. Whilst the magnitude of mean change to scale scores was small, there was a consistent and simultaneous deterioration during maximal androgen blockade (MAB) and improvement during androgen recovery. Older men are more likely to show an impaired testosterone recovery, and this was paralleled by a slower HQOL recovery. Newer methods of analysis to describe results in a way that has meaning to the individual patient are warranted.

LanguageEnglish
Pages1083-1092
Number of pages10
JournalEuropean Journal of Cancer
Volume42
Issue number8
DOIs
Publication statusPublished - May 2006
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Quality of Life
Testosterone
Therapeutics
Leuprolide
Flutamide
Longitudinal Studies
Research

Keywords

  • Androgen suppression
  • Drug therapy
  • Flutamide
  • Health-related quality of life
  • Leuprolide
  • Prostate cancer
  • Testosterone recovery

Cite this

Spry, N. A. ; Kristjanson, L. ; Hooton, B. ; Hayden, L. ; Neerhut, G. ; Gurney, H. ; Corica, T. ; Korbel, E. ; Weinstein, S. ; McCaul, K. / Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. In: European Journal of Cancer. 2006 ; Vol. 42, No. 8. pp. 1083-1092.
@article{4b95c7c5827e482bbb7672ab9decc68b,
title = "Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer",
abstract = "Health-related quality of life (HQOL) research is a means of broadening the assessment of treatment effects. This longitudinal study investigated the dynamic change to quality of life (QOL) and testosterone dependant physiology in men commencing an intermittent maximal androgen blockade program (IMAB). Two hundred and fifty men were accrued to the multi-centre study of IMAB (Flutamide 250 mg TDS, Leuprolide 22.5 mg depot) ceasing treatment after 9 months if PSA <4 ng/ml, and restarting when PSA >20 ng/ml. QOL was assessed every 3 months for 30 months using the EORTC QLQ-C30 and EORTC QLQ-PR25 module. Data completion for the whole study was 90{\%}. At baseline, our cohort was less symptomatic and had better function than the EORTC reference cohort, which may be related to a shift in clinical practice with time. Testosterone suppression (AS) lead to a significant reduction in global HQOL and deterioration in most function and symptom scales. During the off period, there was a trend of progressive improvement in HQOL that paralleled testosterone recovery but was slower than the rate of deterioration during the treatment phase. Maximum recovery of HQOL occurred most frequently by months 9-12. Testosterone recovery was slower and less complete in older men, and lead to concomitant poorer HOQL recovery. Whilst the magnitude of mean change to scale scores was small, there was a consistent and simultaneous deterioration during maximal androgen blockade (MAB) and improvement during androgen recovery. Older men are more likely to show an impaired testosterone recovery, and this was paralleled by a slower HQOL recovery. Newer methods of analysis to describe results in a way that has meaning to the individual patient are warranted.",
keywords = "Androgen suppression, Drug therapy, Flutamide, Health-related quality of life, Leuprolide, Prostate cancer, Testosterone recovery",
author = "Spry, {N. A.} and L. Kristjanson and B. Hooton and L. Hayden and G. Neerhut and H. Gurney and T. Corica and E. Korbel and S. Weinstein and K. McCaul",
year = "2006",
month = "5",
doi = "10.1016/j.ejca.2006.01.029",
language = "English",
volume = "42",
pages = "1083--1092",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Pergamon Press",
number = "8",

}

Spry, NA, Kristjanson, L, Hooton, B, Hayden, L, Neerhut, G, Gurney, H, Corica, T, Korbel, E, Weinstein, S & McCaul, K 2006, 'Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer', European Journal of Cancer, vol. 42, no. 8, pp. 1083-1092. https://doi.org/10.1016/j.ejca.2006.01.029

Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. / Spry, N. A.; Kristjanson, L.; Hooton, B.; Hayden, L.; Neerhut, G.; Gurney, H.; Corica, T.; Korbel, E.; Weinstein, S.; McCaul, K.

In: European Journal of Cancer, Vol. 42, No. 8, 05.2006, p. 1083-1092.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer

AU - Spry, N. A.

AU - Kristjanson, L.

AU - Hooton, B.

AU - Hayden, L.

AU - Neerhut, G.

AU - Gurney, H.

AU - Corica, T.

AU - Korbel, E.

AU - Weinstein, S.

AU - McCaul, K.

PY - 2006/5

Y1 - 2006/5

N2 - Health-related quality of life (HQOL) research is a means of broadening the assessment of treatment effects. This longitudinal study investigated the dynamic change to quality of life (QOL) and testosterone dependant physiology in men commencing an intermittent maximal androgen blockade program (IMAB). Two hundred and fifty men were accrued to the multi-centre study of IMAB (Flutamide 250 mg TDS, Leuprolide 22.5 mg depot) ceasing treatment after 9 months if PSA <4 ng/ml, and restarting when PSA >20 ng/ml. QOL was assessed every 3 months for 30 months using the EORTC QLQ-C30 and EORTC QLQ-PR25 module. Data completion for the whole study was 90%. At baseline, our cohort was less symptomatic and had better function than the EORTC reference cohort, which may be related to a shift in clinical practice with time. Testosterone suppression (AS) lead to a significant reduction in global HQOL and deterioration in most function and symptom scales. During the off period, there was a trend of progressive improvement in HQOL that paralleled testosterone recovery but was slower than the rate of deterioration during the treatment phase. Maximum recovery of HQOL occurred most frequently by months 9-12. Testosterone recovery was slower and less complete in older men, and lead to concomitant poorer HOQL recovery. Whilst the magnitude of mean change to scale scores was small, there was a consistent and simultaneous deterioration during maximal androgen blockade (MAB) and improvement during androgen recovery. Older men are more likely to show an impaired testosterone recovery, and this was paralleled by a slower HQOL recovery. Newer methods of analysis to describe results in a way that has meaning to the individual patient are warranted.

AB - Health-related quality of life (HQOL) research is a means of broadening the assessment of treatment effects. This longitudinal study investigated the dynamic change to quality of life (QOL) and testosterone dependant physiology in men commencing an intermittent maximal androgen blockade program (IMAB). Two hundred and fifty men were accrued to the multi-centre study of IMAB (Flutamide 250 mg TDS, Leuprolide 22.5 mg depot) ceasing treatment after 9 months if PSA <4 ng/ml, and restarting when PSA >20 ng/ml. QOL was assessed every 3 months for 30 months using the EORTC QLQ-C30 and EORTC QLQ-PR25 module. Data completion for the whole study was 90%. At baseline, our cohort was less symptomatic and had better function than the EORTC reference cohort, which may be related to a shift in clinical practice with time. Testosterone suppression (AS) lead to a significant reduction in global HQOL and deterioration in most function and symptom scales. During the off period, there was a trend of progressive improvement in HQOL that paralleled testosterone recovery but was slower than the rate of deterioration during the treatment phase. Maximum recovery of HQOL occurred most frequently by months 9-12. Testosterone recovery was slower and less complete in older men, and lead to concomitant poorer HOQL recovery. Whilst the magnitude of mean change to scale scores was small, there was a consistent and simultaneous deterioration during maximal androgen blockade (MAB) and improvement during androgen recovery. Older men are more likely to show an impaired testosterone recovery, and this was paralleled by a slower HQOL recovery. Newer methods of analysis to describe results in a way that has meaning to the individual patient are warranted.

KW - Androgen suppression

KW - Drug therapy

KW - Flutamide

KW - Health-related quality of life

KW - Leuprolide

KW - Prostate cancer

KW - Testosterone recovery

UR - http://www.scopus.com/inward/record.url?scp=33746387985&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2006.01.029

DO - 10.1016/j.ejca.2006.01.029

M3 - Article

VL - 42

SP - 1083

EP - 1092

JO - European Journal of Cancer

T2 - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 8

ER -